erythromycin has been researched along with ximelagatran in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dorani, H; Eriksson, UG; Fritsch, H; Hoffmann, KJ; Karlsson, J; Olsson, L; Sarich, TC; Schützer, KM; Wall, U | 1 |
| Eriksson, UG; Fridblom, P; Hoffmann, KJ; Knutson, L; Lennernäs, H; Logren, U; Matsson, EM; Petri, N | 1 |
1 review(s) available for erythromycin and ximelagatran
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for erythromycin and ximelagatran
| Article | Year |
|---|---|
Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Antithrombins; Area Under Curve; Azetidines; Benzylamines; Bile; Biotransformation; Cross-Over Studies; Duodenum; Erythromycin; Female; Half-Life; Humans; Intubation, Gastrointestinal; Male; Metabolic Clearance Rate; Models, Biological; Sweden; Young Adult | 2011 |
4 other study(ies) available for erythromycin and ximelagatran
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
Topics: Adult; Animals; Anti-Bacterial Agents; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azetidines; Benzylamines; Bile; Biological Transport, Active; Caco-2 Cells; Calcium Channel Blockers; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Female; Humans; In Vitro Techniques; Male; Partial Thromboplastin Time; Quinidine; Rats; Rats, Sprague-Dawley; Verapamil | 2006 |